Jasper Hellweg
Stock Analyst at Argus Research
(3.45)
# 675
Out of 4,829 analysts
89
Total ratings
50.7%
Success rate
17.39%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Downgrades: Hold | n/a | $124.40 | - | 4 | Apr 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $310.80 | +28.70% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $81.57 | +83.89% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $51.06 | +17.51% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $575.63 | +103.26% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $439.37 | +25.18% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $68.95 | +23.28% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $67.74 | +84.53% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $25.70 | +444.75% | 4 | Sep 13, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $190.07 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $161.92 | +23.52% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $17.96 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $156.13 | +85.74% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $120.70 | -17.15% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $250.94 | +17.56% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.84 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $175.90 | -23.25% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $31.88 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $26.99 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $276.37 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $106.38 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $44.18 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $363.28 | -57.33% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $186.82 | -51.83% | 1 | Sep 19, 2018 |
Biogen
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $124.40
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $310.80
Upside: +28.70%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $81.57
Upside: +83.89%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $51.06
Upside: +17.51%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $575.63
Upside: +103.26%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $439.37
Upside: +25.18%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $68.95
Upside: +23.28%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $67.74
Upside: +84.53%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $25.70
Upside: +444.75%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $190.07
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $161.92
Upside: +23.52%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $17.96
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $156.13
Upside: +85.74%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $120.70
Upside: -17.15%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $250.94
Upside: +17.56%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $5.84
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $175.90
Upside: -23.25%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $31.88
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $26.99
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $276.37
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $106.38
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $44.18
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $363.28
Upside: -57.33%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $186.82
Upside: -51.83%